Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Current Investments (2016 - 2025)

Protalix BioTherapeutics has reported Cash & Current Investments over the past 16 years, most recently at $16.3 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $16.3 million for Q4 2025, up 8.13% from a year ago — trailing twelve months through Dec 2025 was $16.3 million (up 8.13% YoY), and the annual figure for FY2025 was $16.3 million, up 8.13%.
  • Cash & Current Investments for Q4 2025 was $16.3 million at Protalix BioTherapeutics, down from $29.4 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for PLX hit a ceiling of $76.9 million in Q2 2021 and a floor of $15.1 million in Q4 2024.
  • Median Cash & Current Investments over the past 5 years was $34.1 million (2025), compared with a mean of $37.8 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 119.89% in 2021 and later tumbled 66.18% in 2024.
  • Protalix BioTherapeutics' Cash & Current Investments stood at $39.0 million in 2021, then plummeted by 43.11% to $22.2 million in 2022, then soared by 100.9% to $44.6 million in 2023, then tumbled by 66.18% to $15.1 million in 2024, then rose by 8.13% to $16.3 million in 2025.
  • The last three reported values for Cash & Current Investments were $16.3 million (Q4 2025), $29.4 million (Q3 2025), and $33.4 million (Q2 2025) per Business Quant data.